Table 5.

Adjusted difference in neonatal ${\mathrm{T}}_4$ ($\mathrm{\mu }\mathrm{g}/\text{dL}$) per IQR increase in prenatal plasma PFAS concentrations in all neonates and stratified by sex.

PFAS	All ($n=465$)a,b	Male ($n=236$)	Female ($n=229$)
	Beta (95% CI)	Beta (95% CI)	Beta (95% CI)
PFOS	$-0.10$ ($-0.46$, 0.25)	$-0.24$ ($-0.76$, 0.29)	$-0.02$ ($-0.48$, 0.52)
PFOA	$-0.41$ ($-0.88$, 0.06)	$-0.69$ ($-1.44$, 0.07)	$-0.25$ ($-0.85$, 0.36)
PFHxS	$-0.15$ ($-0.38$, 0.08)	$-0.46$ ($-0.83$, $-0.10$)	0.07 ($-0.23$, 0.37)
PFNA	0.05 ($-0.29$, 0.39)	$-0.27$ ($-0.84$, 0.30)	0.23 ($-0.20$, 0.66)
EtFOSAA	$-0.08$ ($-0.27$, 0.11)	0.20 ($-0.30$, 0.71)	$-0.12$ ($-0.32$, 0.08)
MeFOSAA	$-0.12$ ($-0.43$, 0.18)	$-0.08$ ($-0.45$, 0.29)	$-0.28$ ($-0.86$, 0.30)

Note: Adjusted for maternal age, race/ethnicity, smoking status, parity, gestational week at maternal blood draw, cesarean delivery, gestational age, and age at heel stick. EMM z-test p-values: EtFOSAA, 0.23; MeFOSAA, 0.31; PFHxS, 0.02; PFNA, 0.10; PFOA, 0.23; PFOS, 0.30.

^aAdditionally adjusted for infant sex.

^b$n=15$ participants excluded due to missing covariate data.